Top View
- CD47: a New Player in Phagocytosis and Xenograft Rejection
- CD47 Blockade Inhibits Tumor Progression Human Osteosarcoma in Xenograft Models
- Critical Role of Integrin Cd11c in Splenic Dendritic Cell Capture of Missing-Self CD47 Cells to Induce Adaptive Immunity
- 215 AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody
- CD47 Therapeutic Antibody Recognizing a Novel Epitope and Sparing Erythrocytes and Platelets Taylor B
- Original Article CD47 Is Associated with the Up-Regulation of the PD-1 Oncogenic Signaling Pathway
- CD47 Blocking Antibodies Restore Phagocytosis and Prevent Atherosclerosis
- Bbguy Essentials 063CE: Anti-CD47 Testing Interference with Connie Westhoff Released February 6, 2019
- CD47 Blockade to Bridge Innate and Adaptive Immunity
- Expression and Significance of CD44, CD47 and C-Met in Ovarian Clear Cell Carcinoma
- Osteoclast Fusion: Physiological Regulation of Multinucleation Through Heterogeneity— Potential Implications for Drug Sensitivity
- CD47-Sirpα Pathway As a Target for Cancer Therapeutics By
- Innate Immune Checkpoints for Cancer Immunotherapy: Expanding the Scope of Non T Cell Targets
- Dysregulated Integrin Av B3 and CD47 Signaling Promotes Joint
- CD47 Promotes Age-Associated Deterioration in Angiogenesis, Blood Flow and Glucose Homeostasis
- Combining CD47 Blockade with Trastuzumab Eliminates HER2-Positive Breast Cancer Cells and Overcomes Trastuzumab Tolerance
- Dendritic Cells Production and Maturation of Human CD47
- TTI-621 (Sirpafc): a CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding Penka S
- CD47 Blockade Reduces the Pathologic Features of Experimental Cerebral Malaria and Promotes Survival of Hosts with Plasmodium Infection
- SRF231 AACR Poster FINAL
- Thrombospondin-1 CD47 Signalling: from Mechanisms to Medicine
- And Inhibition of Dendritic Cell Activation : Down-Regulation of IL
- Alveolar Epithelial Heparan Sulfate and Chondroitin Sulfate in The
- CD47 Blockade Augmentation of Trastuzumab Antitumor Efficacy Dependent Upon Antibody-Dependent-Cellular-Phagocytosis
- Development of AO-176, a Next Generation Humanized Anti-CD47 Antibody with Novel Anti-Cancer Properties and Negligible Red Blood Cell Binding
- Leukocyte Surface Antigen CD47
- CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity
- SOLUBLE AMYLOID-BETA 42 AGGREGATES STIMULATE CELLULAR INFLAMMATION INDEPENDENT of CD47 Sanjib Karki University of Missouri-St
- UC Davis UC Davis Previously Published Works
- Role of CD47 in Hematological Malignancies Entsar Eladl1, Rosemarie Tremblay-Lemay1, Nasrin Rastgoo1, Rumina Musani1, Wenming Chen2, Aijun Liu2* and Hong Chang1*
- Therapeutic Monoclonal Antibodies & Blood Transfusion
- BRAF/MEK Inhibitors Promote CD47 Expression That Is Reversible by ERK Inhibition in Melanoma
- NIH Public Access Author Manuscript J Bone Miner Res
- CD47–Sirpα: an Interaction of Importance for Bone Cell Differentiation
- Integrin Beta-2
- The Role of Proteoglycans in Cancer Metastasis and Circulating Tumor Cell Analysis
- Correlation of CD47 Expression with Adverse Clinicopathologic Features and an Unfavorable Prognosis in Colorectal Adenocarcinoma
- CD47 Suppresses Phagocytosis by Repositioning SIRPA and Preventing Integrin Activation
- The Microrna-Mediated Regulation of Proteins Implicated In
- LSD1 Silencing Contributes to Enhanced Efficacy of Anti-CD47/PD
- ALX148 Is a High Affinity Sirpα Fusion Protein That Blocks CD47
- Relationship Between Tumor-Associated Macrophage
- Anti-CD47 Antibodies Promote Phagocytosis and Inhibit the Growth of Human Myeloma Cells
- CD47–Signal Regulatory Protein-Α (Sirpα) Interactions Form a Barrier for Antibody-Mediated Tumor Cell Destruction
- Monoclonal Anti-CD47 Interference in Red Cell and Platelet Testing
- CD47 Regulates Bone Mass and Tumor Metastasis to Bone
- Iga Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-Sirpα Checkpoint Inhibition